.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,773,001

« Back to Dashboard

Claims for Patent: 5,773,001

Title: Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
Abstract:This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.
Inventor(s): Hamann; Philip Ross (Garnerville, NY), Hinman; Lois (N. Tarrytown, NY), Hollander; Irwin (Monsey, NY), Holcomb; Ryan (Glen Rock, NJ), Hallett; William (New City, NY), Tsou; Hwei-Ru (New City, NY), Weiss; Martin J. (Ft. Lee, NJ)
Assignee: American Cyanamid Company (Madison, NJ)
Application Number:08/253,877
Patent Claims: 1. A cytotoxic drug conjugate of formula:

wherein

Z.sup.3 is a protein selected from mono- and polyclonal antibodies, their antigen-recognizing fragments, and their chemically or genetically manipulated counterparts, and growth factors and their chemically or genetically manipulated counterparts, wherein a covalent bond to the protein is an amide formed from reaction with lysine side chains, or a steroid, wherein the covalent bond to the steroid is an amide or an ester;

Alk and Alk.sup.2 are independently a bond or branched or unbranched (C.sub.1 -C.sub.10) alkylene chain;

Sp.sup.1 is a bond, --S--, --O--, --CONH--, --NHCO--, --NR'--, --N(CH.sub.2 CH.sub.2).sub.2 N--, or --X--Ar'--Y--(CH.sub.2).sub.n --Z wherein X, Y, and Z are independently a bond, --NR'--, --S--, or --O--, with the proviso that when n=0, then at least one of Y and Z must be a bond and Ar' is 1,2-, 1,3-, or 1 ,4-phenylene optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.5) alkyl, (C.sub.1 -C.sub.4) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR', with the proviso that when Alk.sup.1 is a bond, Sp.sup.1 is a bond;

n is an integer from 0 to 5;

R' is a branched or unbranched (C.sub.1 -C.sub.5) chain optionally substituted by one or two groups of --OH, (C.sub.1 -C.sub.4) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, (C.sub.1 -C.sub.3) dialkylamino, or (C.sub.1 -C.sub.3) trialkylammonium --A.sup.- where A.sup.- is a pharmaceutically acceptable anion completing a salt;

Ar is 1,2-, 1,3-, or 1,4-phenylene optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.5) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, or COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined above or a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3-, 2,6-, or 2,7-naphthylidene or ##STR15## each naphthylidene or phenothiazine optionally substituted with one, two, three, or four groups of (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.5) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, or COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined above, with the proviso that when Ar is naphthylidene, Z.sup.1 is not hydrogen and with the proviso that when Ar is phenothiazine, Sp.sup.1 is a bond only connected to nitrogen;

Sp.sup.2 is a bond, --S--, or --O--, with the proviso that when Alk.sup.2 is a bond, Sp.sup.2 is a bond;

Z.sup.1 is H, (C.sub.1 -C.sub.5) alkyl, or phenyl optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.5) alkyl, (C.sub.1 -C.sub.4) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2),CONHR' wherein n and R' are as defined above;

Z.sup.2 is Q--Sp--S--S--W, wherein W is ##STR16## R.sub.5 is --CH.sub.3, --C.sub.2 H.sub.5, or --CH(CH.sub.3).sub.2 ; X is an iodine or bromine atom; R.sub.5' is a hydrogen or the group RCO, wherein R is hydrogen, branched or unbranched (C.sub.1 -C.sub.10) alkyl or (C.sub.1 -C.sub.10) alkylene group, a (C.sub.6 -C.sub.1 l) aryl group, a (C.sub.6 -C.sub.11) aryl-alkyl (C.sub.1 -C.sub.5) group, or a heteroaryl or heteroaryl- alkyl (C.sub.1 -C.sub.5) group wherein heteroaryl is 2- or 3-furyl, 2- or 3-thienyl, 2- or 3-(N-methylpyrrolyl), 2-, 3-, or 4-pyridyl, 2-, 4-, or 5-(N-methylimidizolyl), 2-, 4-, or 5-oxazolyl, 2-, 3-, 5-, or 6-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, or 1-, 3-, 4-, 5-, 6-, 7-, or 8-heteroaryl optionally substituted by one or more hydroxy, amino, carboxy, halo, nitro, lower (C.sub.1 -C.sub.3) alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups;

Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18) radical, divalent or trivalent aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent aryl- or heteroaryl-alkyl (C.sub.1 -C.sub.18) radical, divalent or trivalent cycloalkyl- or heterocycloalkyl-alkyl (C.sub.1 -C.sub.18) radical or divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is furyl, thienyl, N-methylpyrrolyl, pyridinyl, N-methylimidazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolyl, N-methylcarbazoyl, aminocoumarinyl, or phenazinyl and wherein when Sp is a trivalent radical, Sp can be additionally substituted by lower (C.sub.1 -C.sub.5) dialkylamino, lower (C.sub.1 -C.sub.5) alkoxy, hydroxy, or lower (C.sub.1 -C.sub.5) alkylthio groups; and

Q is .dbd.NHNCO--, .dbd.NHNCS--, .dbd.NHNCONH--, .dbd.NHNCSNH--, or .dbd.NHO--

m is from about 0.1 to 15.

2. A cytotoxic drug conjugate according to claim 1 wherein

Alk.sup.2 is a branched or unbranched (C.sub.1 -C.sub.10) alkylene chain and

Z.sup.1 is phenyl optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.5) alkyl, (C.sub.1 -C.sub.4) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined in claim 1.

3. A cytotoxic drug conjugate according to claim 1 wherein

Alk.sup.2 and Sp.sup.2 are together a bond and

Z.sup.1 is H or (C.sub.1 -C.sub.5) alkyl.

4. A cytotoxic drug conjugate according to claim 2 or claim 3 wherein Sp.sup.1 is a bond, --S--, --O--, --CONH--, --NHCO--, or --NR' wherein R' is defined in claim 1.

5. A cytotoxic drug conjugate according to claim 4 wherein

Ar is 1,2-, 1,3-, or 1,4-phenylene optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.5) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, or COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined in claim 1 or Ar is a 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3-, 2,6-, or 2,7-naphthylidene each optionally substituted with one, two, three, or four groups of (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.5) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, or COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined in claim 1.

6. A cytotoxic drug conjugate according to claim 5 wherein

Z.sup.3 is a protein selected from mono- and polyclonal antibodies, their antigen-recognizing fragments, and their chemically or genetically manipulated counterparts and growth factors and their chemically or genetically manipulated counterparts, wherein a covalent bond to the protein is an amide formed from reaction with "m" lysine side chains.

7. A cytotoxic drug conjugate according to claim 6 wherein

Z.sup.2 is Q--Sp--S--S--W, wherein W is ##STR17## R.sub.5, X, R.sub.5 ', and Sp are as defined in claim 1; and Q is .dbd.NHNCO--.

8. A cytotoxic drug conjugate according to claim 7 wherein

Ar is 1,2-, 1,3-, or 1,4-phenylene optionally substituted with one, two, or three groups of (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.5) alkoxy, (C.sub.1 -C.sub.4) thioalkoxy, halogen, nitro, or COOR', CONHR', O(CH.sub.2).sub.n COOR', S(CH.sub.2).sub.n COOR', O(CH.sub.2).sub.n CONHR', or S(CH.sub.2).sub.n CONHR' wherein n and R' are as defined in claim 1,

Alk.sup.2 and Sp.sup.2 are together a bond, and

Z.sup.1 is H or (C.sub.1 -C.sub.5) alkyl.

9. A cytotoxic drug conjugate according to claim 8, wherein

Sp.sup.1 is --O-- or a bond,

Alk.sup.1 is C.sub.1 to C.sub.6 alkylene,

Ar is 1,3- or 1,4-phenylene oDtionallv substituted with one or two groups of (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, halogen, nitro, COOR', or CONHR' wherein R' is as defined in claim 1, and

Z.sup.1 is (C.sub.1 -C.sub.3) alkyl.

10. A cytotoxic drug conjugate according to claim 9 wherein

Z.sup.3 is antibody h-P67.6, h-CT-M-01, or h-A33 and

Z.sup.2 is Calicheamicin gamma dimethyl hydrazide or Calicheamicin N-acetyl gamma dimethyl hydrazide.

11. A cytotoxic drug conjugate according to claim 10 wherein

Z.sup.3 is antibody h-CT-M-01 and

Z.sup.2 is Calicheamicin N-acetyl gamma dimethyl hydrazide.

12. A cytotoxic drug conjugate according to claim 10 wherein

Z.sup.3 is antibody h-P67.6 and

Z.sup.2 is Calicheamicin N-acetyl gamma dimethyl hydrazide.

13. A pharmaceutical composition for inhibiting the growth of cells, comprising an effective cell growth-inhibiting amount of the conjugate of claim 1 and a parenterally-administrable medium.

14. A pharmaceutical composition for inhibiting the growth of cells, comprising an effective cell growth-inhibiting amount of the conjugate of claim 11 and a parenterally-administrable medium.

15. A method of inhibiting the growth of or eliminating a an undesirable cell in a patient comprising administering the conjugate of claim 1 to a patient.

16. A method of inhibiting the growth of or eliminating a an undesirable cell in a Datient comprising administering the conjugate of claim 11 to a patient.

17. The method of claim 15, wherein the cell is a cancer cell in a mammalian species.

18. A freeze-dried pharmaceutical composition for inhibiting the growth of cells, comprising a conjugate of claim 11 which is obtained by freeze-drying an approximately 1 mg/mL solution of the conjugate dissolved in about 5 mM sodium phosphate buffer at a pH of about 7.4 containing about 100 mM sodium chloride and about 100 mM sucrose.

19. A cytotoxic drug conjugate according to claim 8 wherein

Sp.sup.1 is --O-- or a bond,

Alk.sup.1 is a bond or branched or unbranched (C.sub.1 -C.sub.10) alkylene chain, with the proviso that when Alk.sup.1 is a bond, Sp.sup.1 is a bond,

Z.sup.1 is (C.sub.1 -C.sub.5) alkyl, and

Z.sup.2 is Calicheamicin N-acetyl gamma dimethyl hydrazide.

20. A pharmaceutical composition for inhibiting the growth of cells, comprising an effective cell growth-inhibiting amount of the conjugate of claim 12 and a parenterally-administrable medium.

21. A method of inhibiting the growth of or eliminating an undesirable cell in a patient comprising administering the conjugate of claim 12 to a patient.

22. The method of claim 16, wherein the cell is a cancer cell in a mammalian species.

23. The method of claim 21 wherein the cell is a cancer cell in a mammalian species.

24. A freeze-dried pharmaceutical composition for inhibiting the growth of cells, comprising a conjugate of claim 12 which is obtained by freeze-drying an approximately 1 mg/mL solution of the conjugate dissolved in about 5 mM sodium phosphate buffer at a pH of about 7.4 containing about 100 mM sodium chloride and about 100 mM sucrose.

25. A cytotoxic drug conjugate according to claim 9, wherein

Z.sup.3 is a monoclonal antibody which recognizes the CD33 antigen and

Z.sup.2 is calicheamicin gamma dimethyl hydrazide or calicheamicin N-acetyl gamma dimethyl hydrazide.

26. A cytotoxic drug conjugate according to claim 9, wherein

Z.sup.3 is a monoclonal antibody which recognizes the polyepithelial mucin antigen and

Z.sup.2 is calicheamicin gamma dimethyl hydrazide or calicheamicin N-acetyl gamma dimethyl hydrazide.

27. A cytotoxic drug conjugate according to claim 9, wherein

Z.sup.3 is a monoclonal antibody which recognizes a glycoprotein antigen present on colon cancer cells and

Z.sup.2 is calicheamicin gamma dimethyl hydrazide or calicheamicin N-acetyl gamma dimethyl hydrazide.

28. A cytotoxic drug conjugate according to claim 9, wherein

Z.sup.3 is a monoclonal antibody which recognizes the IL2 receptor found on cells selected from the group consisting of activated and functionally mature T cells and abnormally activated leukemia cells and

Z.sup.2 is calicheamicin gamma dimethyl hydrazide or calicheamicin N-acetyl gamma dimethyl hydrazide.

29. A cytotoxic drug conjugate according to claim 9, wherein

Z.sup.3 is antibody h-P67.6,

Z.sup.2 is calicheamicin N-acetyl gamma dimethyl hydrazide,

Sp.sup.1 is --O--,

Alk.sup.1 is C.sub.3 alkylene,

Ar is 1,4-phenylene, and

Z.sup.1 is C.sub.1 alkyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc